Skip to main content
PMC home page
Nature Portfolio logoLink to Nature Portfolio
. 2016 Dec 1;40(4):376–384. doi: 10.1038/hr.2016.158

Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial

Seiji Umemoto 1,*, Toshio Ogihara 2,3, Masunori Matsuzaki 4, Hiromi Rakugi 3, Yasuo Ohashi 5, Takao Saruta 6; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group*
PMCID: PMC5506236  PMID: 27904156

Abstract

We compared three benidipine-based regimens—that is, benidipine plus angiotensin receptor blocker (ARB), β-blocker (BB) or thiazide—and found that the benidipine–BB combination was less beneficial in reducing the risk of stroke than the benidipine–thiazide combination. This sub-analysis sought to compare the effects of reaching a target blood pressure (BP) (<140/90 mm Hg) on the cardiovascular outcomes among the three benidipine-based treatment groups in the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. This sub-analysis included 3001 subjects to evaluate the achievement of target BP at a minimum of three points at 6-month intervals of clinical BP measurements during the study period. After randomization, the patients were categorized into two groups on the basis of achieved on-treatment target BP: a good control (GC) group achieving a BP⩾66.7% of the target and a poor control (PC) group with a BP <66.6% of the target. For each of the two control groups, outcomes were compared among the three treatment groups. The event rates for cardiovascular composite endpoints, stroke and hard cardiovascular events were higher in the PC group than the GC group (P=0.041, P=0.042 and P=0.038, respectively). Within the PC group, hazard ratios for the incidence of cardiovascular events were lower in the benidipine–thiazide group than in the benidipine–BB group (composite cardiovascular events: 2.04, P=0.033; stroke: 4.14, P=0.005; and hard cardiovascular events: 3.52, P=0.009). Within the GC group, the incidence of cardiovascular events was not different among the three treatment regimens. The benidipine–thiazide combination may provide better cardiovascular outcomes than the benidipine–BB combination even in patients with poor BP control.

Keywords: β-blocker, calcium channel blockers, diuretics, drug combination therapy, target blood pressure control, thiazide

Introduction

Previous meta-analyses have shown that anti-hypertensive agents are effective in lowering blood pressure (BP) and preventing cardiovascular events,1, 2, 3, 4, 5, 6 but two or more agents are often required to achieve the target BP,7, 8 and recent clinical guidelines have recommended combination therapy to control BP levels.9, 10, 11 Although the adverse cardiovascular consequences of hypertension largely depend on the absolute BP values,12 current guidelines recommend <140/90 mm Hg as the target level of BP control based on the results of comparative studies.9, 10, 11

The Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) trial was the first clinical trial to examine combination therapy with a potent and long-acting dihydropyridine calcium channel blocker (CCB), benidipine, which inhibits not only L-type and N-type calcium channels but also T-type calcium channels,13 for the treatment of hypertension. In this trial, although the percentages of subjects achieving the target BP (<140/90 mm Hg) and the incidences of primary composite cardiovascular endpoints, including the reduction in BP from baseline over the course of the trial, were similar among the benidipine–thiazide diuretic (thiazide), benidipine–angiotensin receptor blocker (ARB) and benidipine–β-blocker (BB) groups, secondary analyses suggested that benidipine combined with a BB was less effective at reducing the risk of stroke compared with the benidipine–thiazide combination.14, 15, 16, 17, 18

Many clinical trials have directly compared the effects of anti-hypertensive medications on BP reduction and cardiovascular outcomes,2, 3, 4, 5, 6 but there is little evidence concerning the effects of anti-hypertensive medications on these indices in patients with hypertension who do not achieve the target BP. Further, there are no data on the cardiovascular outcome of combination therapy in patients who do not achieve the target BP. In the present study, therefore, we analyzed the data on patients with hypertension who were enrolled in the COPE trial and who did not achieve the target BP following monotherapy with benidipine at a dose of 4 mg per day. We categorized these patients on the basis of their on-treatment BPs to assess the impact of not achieving the target BP (⩾140 mm Hg) compared with achieving the target BP (<140/90 mm Hg) on cardiovascular outcome among the three benidipine-based treatment groups in the COPE trial.

Methods

Study design

The COPE trial was an investigator-initiated multi-center study with a prospective, randomized, open-label, blinded-endpoint design that compared cardiovascular effects and the achievement of a target BP (<140/90 mm Hg) between three dihydropyridine-type CCB benidipine-based regimens (ARB, BB or thiazide) in 3501 hypertensive patients who had not achieved the target BP with benidipine alone at a dose of 4 mg per day. The BP management titration algorithm, together with other details of the study design, and the results of the COPE trial have already been reported.14, 15 In brief, participants aged 40–85 years with a sitting systolic BP of 140 mm Hg or more and/or a diastolic BP of 90 mm Hg or more, whether untreated or treated, who did not achieve the target BP at our clinic following monotherapy with benidipine at a dose of 4 mg per day during the run-in phase (4–8 weeks) were included in the study. These patients were randomly assigned to receive benidipine combined with an ARB, a BB or a thiazide. After the randomization, all patients were followed every 6 months for at least 36 months (BP measurement phase). The BP was measured at randomization (baseline), at monthly intervals to achieve the target BP after randomization (drug titration phase), and every 6 months thereafter according to the guidelines for the management of hypertension.19 Mean on-treatment BP measurements were obtained at 6-month intervals from 6 months of the study treatment onwards.

The primary composite cardiovascular events consisted of the following groups: subjects with sudden death, fatal or non-fatal stroke, fatal or non-fatal myocardial infarction, hospitalization due to unstable angina, new onset of heart failure (New York Heart Association class II–IV), new onset or worsening of peripheral arterial disease, and renal events (defined as serum creatinine level doubled to over 2 mg dl−1, serum creatinine ⩾4.0 mg dl−1 or renal dialysis). The secondary endpoints were defined as all-cause mortality, death from cardiovascular events, hard composite cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke excluding transient ischemic attack) and new onset of diabetes.

Data analysis

A total of 3293 patients who were prescribed a combination treatment (1110, benidipine–ARB; 1089, benidipine–BB; 1094, benidipine–thiazide) were compared using full set analysis to specifically evaluate the effects of benidipine-based combination therapy for hypertension in the COPE trial.15 BP measured on six occasions from 6 to 36 months after randomization was used to determine the achievement of target BP during the 3-year BP measurement phase from 6-month interval clinic BP measurements during the study period. After excluding 292 patients who were missing BP values for at least four out of the six measurement time points, 3001 patients (1031, benidipine–ARB; 975, benidipine–BB; 995, benidipine–thiazide) were eligible for the present study. The median percentage of target BP achieved in the subjects in this sub-analysis was 66.7%, and the previous results on the visit-to-visit BP variability in the post-hoc analysis of the COPE trial showed that lower visit-to-visit BP variability may be important for better outcomes.18 In consideration of all of these results on the BP control, we categorized the sub-analysis subjects into two groups based on whether they achieved on-treatment target BP of at least four points of the mean on-treatment BPs obtained at 6-month intervals from 6 months of study treatment onwards: the good control (GC) group was defined as patients who achieved a target BP⩾66.7%, and the poor control (PC) group was defined as patients who achieved target BP<66.6% from 6 months of study treatment onwards (Figure 1). The median follow-up period was 3.67 years after randomization, and 3.1 years after the 6-month visit.

Figure 1.

Figure 1

Open in a new tab

Flow diagram of the study participants. ARB, angiotensin receptor blocker; BB, β-blocker; TD, thiazide diuretic.

Statistical analysis

Patient characteristics were reported as the mean±s.d. or percentage. Continuous variables were compared with Student’s t-tests or one-way analysis of variance, as appropriate. Categorical variables were compared with the χ2-test. Survival curves were generated by the Kaplan–Meier method for primary composite cardiovascular events and secondary cardiovascular events among the three treatment groups. Survival curves were compared using the log-rank test. Hazard ratios (HRs) and confidence intervals were calculated using the Cox proportional hazards model. All data were analyzed using SAS System Release 9.1 (SAS Institute, Cary, NC, USA). All reported P-values are two-sided.

Results

Data on the demographic and baseline characteristics showed that the body mass index, systolic and diastolic BPs, diabetes, total anti-hypertensive agents, benidipine, ARB and anti-diabetic agents were significantly higher in the PC group than the GC group (Table 1). Others characteristics were well-matched between the two groups in this sub-analysis of the COPE trial. In addition, within the GC group all of the demographic and baseline characteristics were well-matched among the three randomized groups, with the exception that the percentage of angiotensin-converting enzymes was significantly higher in the benidipine–BB group than the other two groups (Table 2).

Table 1. Demographic and baseline characteristics of the cohort on the basis of achieved on-treatment blood pressure control.

  Good control (n=1733) Poor control (n=1268) P-value
Sex, male 872 (50.3) 636 (50.2) 0.931
Age, years 63.2±10.4 63.4±11.0 0.574
BMI, kg m−2 24.4±3.4 24.7±3.4 0.042
Systolic BP, mm Hg 151.4±10.2 157.3±12.4 <0.001
Diastolic BP, mm Hg 88.1±9.3 89.4±10.2 <0.001
Heart rate, beat per min 74.0±11.0 74.4±11.5 0.320
Previous CV disease 207 (11.9) 168 (13.2) 0.286
Diabetes 204 (11.8) 223 (17.6) <0.001
Dyslipidemia 702 (40.5) 515 (40.6) 0.953
Current smoking 688 (39.7) 486 (38.3) 0.447
Anti-hypertensive agents 1362 (78.6) 1061 (83.7) <0.001
 Benidipine 1076 (62.1) 835 (65.9) 0.034
 Other CCB 183 (10.6) 161 (12.7) 0.069
 ARB 142 (8.2) 143 (11.3) 0.004
 ACE inhibitor 36 (2.1) 17 (1.3) 0.130
 BB 56 (3.2) 36 (2.8) 0.538
 Diuretics 13 (0.8) 18 (1.4) 0.073
 α-Blocker 11 (0.6) 6 (0.5) 0.560
       
Concomitant medication
 Anti-platelets 138 (8.0) 103 (8.1) 0.873
 Lipid-lowering agents 378 (21.8) 261 (20.6) 0.417
  Statin 303 (17.5) 203 (16.0) 0.287
 Antidiabetic agents 97 (5.6) 115 (9.1) <0.001
Open in a new tab

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, β-blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CV, cardiovascular.

Data are shown as the number of patients (%) or mean±s.d. Differences in the proportions between the good and poor control groups were analyzed using the χ2-test or unpaired t-test.

Table 2. Demographic and baseline characteristics of the cohort on the basis of achieved on-treatment target blood pressure control.

  Good control
   Poor control
  
  Benidipine plus ARB (n=592) Benidipine plus BB (n=577) Benidipine plus TD (n=564) P-value Benidipine plus ARB (n=439) Benidipine plus BB (n=398) Benidipine plus TD (n=431) P-value
Sex, male 297 (50.2) 287 (49.7) 288 (51.1) 0.901 226 (51.5) 200 (50.3) 210 (48.7) 0.718
Age, years 62.5±10.3 63.4±10.5 63.8±10.3 0.093 63.8±11.0 63.3±11.0 63.1±11.1 0.675
BMI, kg m−2 24.6±3.4 24.4±3.4 24.4±3.4 0.661 24.8±3.4 24.9±3.4 24.4±3.3 0.099
Systolic BP, mm Hg 151.0±10.6 151.4±9.6 151.7±10.2 0.525 157.6±12.2 156.8±11.7 157.4±13.2 0.656
Diastolic BP, mm Hg 88.5±9.2 88.0±9.4 87.9±9.3 0.531 89.7±10.4 89.2±9.9 89.3±10.3 0.736
Heart rate, beat per min 73.9±11.1 74.7±10.9 73.3±11.0 0.140 74.1±11.2 73.8±11.1 75.4±12.1 0.146
Previous CV desease 66 (11.1) 63 (10.9) 78 (13.8) 0.242 67 (15.3) 49 (12.3) 52 (12.1) 0.305
Diabetes 67 (11.3) 65 (11.3) 72 (12.8) 0.671 78 (17.8) 74 (18.6) 71 (16.5) 0.720
Dyslipidemia 238 (40.2) 235 (40.7) 229 (40.6) 0.982 164 (37.4) 159 (39.9) 192 (44.5) 0.092
Current smoking 234 (39.5) 220 (38.1) 234 (41.5) 0.507 168 (38.3) 161 (40.5) 157 (36.4) 0.492
Anti-hypertensive agents 462 (78.0) 456 (79.0) 444 (78.7) 0.915 367 (83.6) 331 (83.2) 363 (84.2) 0.918
 Benidipine 364 (61.5) 363 (62.9) 349 (61.9) 0.875 287 (65.4) 262 (65.8) 286 (66.4) 0.954
 Other CCB 65 (11.0) 60 (10.4) 58 (10.3) 0.918 56 (12.8) 50 (12.6) 55 (12.8) 0.995
 ARB 47 (7.9) 48 (8.3) 47 (8.3) 0.962 47 (10.7) 47 (11.8) 49 (11.4) 0.878
 ACE inhibitor 15 (2.5) 11 (1.9) 10 (1.8) 0.623 2 (0.5) 12 (3.0) 3 (0.7) 0.002
 BB 13 (2.2) 20 (3.5) 23 (4.1) 0.180 11 (2.5) 15 (3.8) 10 (2.3) 0.398
 Diuretics 3 (0.5) 4 (0.7) 6 (1.1) 0.538 7 (1.6) 4 (1.0) 7 (1.6) 0.700
 α-Blocker 2 (0.3) 7 (1.2) 2 (0.4) 0.101 3 (0.7) 3 (0.8) 0 (0.0) 0.209
                 
Concomitant medication
 Anti-platelets 43 (7.3) 46 (8.0) 49 (8.7) 0.670 47 (10.7) 27 (6.8) 29 (6.7) 0.050
 Lipid-lowering agents 132 (22.3) 125 (21.7) 121 (21.5) 0.936 87 (19.8) 82 (20.6) 92 (21.3) 0.856
  Statin 106 (17.9) 103 (17.9) 94 (16.7) 0.824 69 (15.7) 68 (17.1) 66 (15.3) 0.769
 Anti-diabetic agents 31 (5.2) 28 (4.9) 38 (6.7) 0.343 40 (9.1) 41 (10.3) 34 (7.9) 0.481
Open in a new tab

Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BB, β-blocker; BMI, body mass index; BP, blood pressure; CCB, calcium channel blocker; CV, cardiovascular.

Data are shown as the number of patients (%) or mean±s.d. Differences in the proportions between the good and poor control groups were analyzed using the χ2-test or one-way analysis of variance.

The reduction in BP from baseline was similar among the three treatment groups in both the GC and PC groups over the course of the trial (Figure 2). At the end of the BP measurement phase, the mean average BPs in the GC and PC groups were ~128/74 mm Hg and 142/80 mm Hg, respectively. The average BP did not differ among the three treatment groups in either the GC or PC subjects. Moreover, the percentage of patients who achieved the target BP did not differ among the three treatment groups in either the GC or PC subjects, whereas the percentage of patients who achieved the target BP was higher in the GC group than in the PC group (85.9 vs. 36.1%).

Figure 2.

Figure 2

Open in a new tab

Effects of treatment on mean systolic and diastolic BP and achievements of target BP. ARB, angiotensin receptor blocker; BB, β-blocker; BP, blood pressure; TD, thiazide diuretic. Data of the proportions of target blood pressure are shown as percentage of patients. Achievement rate is the proportion of patients achieving target BP (systolic BP<140 mm Hg and diastolic BP<90 mm Hg).

Trends in the concomitant medications did not appear to differ among the three treatment groups in either the GC or PC subjects (Supplementary Table S1). However, at the 36-month follow-up, the concomitant use of lipid-lowering agents and statins was significantly higher in the PC group than the GC group (Supplementary Table S2).

Hazzard ratios

The event rates for the primary composite cardiovascular events, hard composite cardiovascular events and stroke were significantly higher in the PC group than in the GC group (Table 3): the HRs of primary composite cardiovascular events, hard composite cardiovascular events, and stroke were significantly higher in the benidipine–BB group than in the benidipine–thiazide group of the PC group, whereas they did not differ among the three treatment groups of the GC group. We further calculated the HRs by the multi-adjusted and adjusted with the systolic BP with time-dependent covariates in this sub-analysis for the primary composite cardiovascular events, hard composite cardiovascular events and stroke (Supplementary Table S3), demonstrating that the results of this sub-analysis of the COPE trial confirmed that the influence of the BP difference among the three treatment groups in the PC group on outcomes was negligible. In contrast, compared with the benidipine–ARB group, the HR of the incidence of new-onset diabetes was significantly higher in the benidipine–BB group than in the other two treatment groups in the GC group, whereas it did not differ among the three treatment groups of the PC group (Figure 3). In contrast, the HRs of cardiac events and all-cause mortality were not different among the three treatment groups in both the GC and PC groups.

Table 3. Incidence of primary and secondary endpoints.

  Good control (n=1733) Poor control (n=1268) P-value (log-rank)
Primary endpoints
 Composite cardiovascular events 53 (8.2) 56 (12.1) 0.041
       
Secondary endpoints
 Hard composite cardiovascular events 27 (4.1) 33 (7.1) 0.038
 Fatal and non-fatal stroke including TIA 21 (3.2) 27 (5.8) 0.042
 Cardiac events 24 (3.7) 25 (5.3) 0.196
 All-cause mortality 33 (5.0) 28 (5.9) 0.474
 New-onset diabetes 56 (8.7) 34 (7.3) 0.397
Open in a new tab

Abbreviation: TIA, transient ischemic attack.

Hard composite cardiovascular events were consist of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke. Differences in the primary and secondary events between the good control group and the poor control group were analyzed using Tukey’s multiple comparison test. Data are shown as incidence number (per 1000 patients years).

Figure 3.

Figure 3

Open in a new tab

Hazard ratios for primary and secondary endpoints. A primary composite cardiovascular events consisted of the following groups: sudden death; fatal or non-fatal stroke; fatal or non-fatal myocardial infarction; hospitalization due to unstable angina; new onset of heart failure (New York Heart Association class II–IV); new onset or worsening of peripheral arterial disease; and renal events (defined as serum creatinine level doubled to over 2 mg dl−1, serum creatinine ⩾4.0 mg dl−1 or renal dialysis). Hard composite cardiovascular events consist of cardiovascular death, fatal or non-fatal myocardial infarction and stroke excluding TIA. ARB, angiotensin receptor blocker; BB, β-blocker; CI, confidence interval; CV, cardiovascular; TD, thiazide diuretic; TIA, transient ischemic attack.

Primary and secondary outcomes

The survival curves for time to first composite cardiovascular endpoints, hard composite endpoints and stroke in both the PC and GC groups (Figure 4) showed that compared with the benidipine–thiazide group of the PC group, primary composite cardiovascular endpoints (Figure 4a), hard composite cardiovascular events (Figure 4b) and stroke (Figure 4c) were significantly higher only in the benidipine–BB group, whereas the difference in these endpoints among the three treatment groups did not differ in the GC group. The incidence of the primary composite cardiovascular endpoints, hard composite cardiovascular events and stroke in the benidipine–ARB group was higher than in the benidipine–thiazide group and lower than the benidipine–BB group, but the incidence of these endpoints in the benidipine–ARB regimen did not differ from the benidipine–thiazide or the benidipine–BB group in both the PC and GC groups (Figure 4).

Figure 4.

Figure 4

Open in a new tab

Kaplan–Meier curves for time to first primary and secondary endpoint. Primary composite cardiovascular events: sudden death, fatal or non-fatal stroke, fatal or non-fatal myocardial infarction, hospitalization due to unstable angina, new onset of heart failure (New York Heart Association class II–IV), new onset or worsening of peripheral arterial disease, and renal events (defined as serum creatinine level doubled to over 2 mg dl−1, serum creatinine ⩾4.0 mg dl−1, or renal dialysis). Hard composite cardiovascular events; cardiovascular death, non-fatal myocardial infarction and non-fatal stroke excluding transient ischemic attack. ARB, angiotensin receptor blocker; BB, β-blocker; CV, cardiovascular; TD, thiazide diuretic; TIA, transient ischemic attack.

Adverse events

The percentage of total adverse events was similar in both the PC and GC groups: 613 (48.3%) and 613 (48.3%) patients reported adverse events, respectively (Supplementary Table S4). In addition, the percentage of total adverse events was also similar among the three treatment groups in both the PC and GC groups (Supplementary Table S4). In the PC group, the following adverse events were more frequent than in the GC group: increased glycosylated hemoglobin (1.6 and 0.6% P<0.012); proteinuria (1.5 and 0.7% P=0.031); cardiac failure (0.9 and 0.2% P<0.006); and thrombotic stroke (0.7 and 0.1% P=0.008), as shown in Supplementary Table S4.

Discussion

The most important and surprising findings in this sub-analysis from the COPE trial were that the benidipine–thiazide combination may provide better cardiovascular outcome than the benidipine–BB combination even in patients with poor BP control, whereas no significant differences on cardiovascular outcome were observed among the three benidipine-based combinations in the patients with good BP control.

Current guidelines for the management of hypertension9, 11, 20 recommend a BP<140/90 mm Hg as a target BP to reduce the incidence of cardiovascular disease. In this sub-analysis, we confirm that the achievement of this target BP is important and that the three allocated classes of anti-hypertensive agents used in the COPE trial are suitable for the CCB, benidipine-based combination to reduce the incidence of cardiovascular disease when sufficiently achieving the target BP. In contrast, when the target BP is insufficiently achieved throughout the BP measurement phase by the benidipine-based combinations, the benidipine–thiazide regimen may be better to prevent the incidence of cardiovascular outcome than the benidipine–BB regimen even if the mean BPs are higher than the target BP. We recently reported that the benidipine–thiazide combination may reduce intra-individual visit-to-visit BP variability more than the benidipine–BB combination,18 suggesting that visit-to-visit BP variability is greater when mean BP is higher.21 These findings indicate that even when target BP is insufficiently achieved, the reduction of intra-individual visit-to-visit BP variability may be important to reduce cardiovascular events in patients with hypertension.

In this sub-analysis of the COPE trial, the mean average BPs at the end of the BP measurement phase in the GC and PC groups were ~128/74 mm Hg and 142/80 mm Hg, respectively. In addition, the cardiovascular event rates for the benidipine–thiazide combination in the PC group were similar to the cardiovascular event rates for this combination in the GC group (Figure 4). Recently, the SPRINT Research Group22 reported that among patients at high risk for cardiovascular events but without diabetes, targeting a systolic BP <120 mm Hg, compared with <140 mm Hg, resulted in lower rates of fatal and non-fatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group. In their study, the drugs were mainly dihydropyridine-type CCBs, angiotensin-converting enzyme inhibitors or ARBs, and diuretics and the mean systolic BP at 1 year was 121.4 mm Hg in the intensive-treatment group and 136.2 mm Hg in the standard-treatment group. Although the COPE trial15 mainly included lower-risk patients with fewer cardiovascular complications compared with those in the SPRINT research,22 the SPRINT sub-analysis also showed lower rates of fatal and non-fatal major cardiovascular events in the GC group, indicating that the results of our sub-analysis may support the results of the SPRINT research.22 Moreover, the benidipine–thiazide combination may result in better cardiovascular outcomes in hypertensive patients compared with the benidipine–BB combination, when the target BP was insufficiently achieved.

Study limitations

We adopted the prospective, randomized, open-label, blinded-endpoint design and the sample size and cardiovascular events of this sub-analysis of the COPE trial were relatively small,15, 16, 17, 23 which could have induced a bias and led to chance findings. Because combination therapies are often needed for high-risk patients,21 the optimal combination in mildly to moderately hypertensive patients should be investigated in future clinical trials. In addition, this sub-analysis of a randomized trial was not specifically designed to test various BP targets. Moreover, the results are applicable only to hypertensive patients 40–85 years of age with a BP of ⩾140/90 after benidipine-based monotherapy at entry. In addition, the number of visits in the COPE trial varied among patients (a minimum of three visits was required), although the mean number of BP measurements per patient did not differ significantly between the 3 treatment groups during the 36-month BP measurement phase.

Conclusions

In this sub-analysis of the COPE trial, the benidipine–thiazide combination provided better cardiovascular outcome than the benidipine–BB combination even in subjects with poor BP control. Indeed, we demonstrated that this combination may be better not only for lowering the BP level but also for reducing stroke and other cardiovascular events compared with the benidipine–BB combination. This may be true even in patients who have insufficiently achieved the target BP (⩾140/90 mm Hg). Hence, this combination may provide better cardiovascular outcomes, especially in terms of stroke incidence, in hypertensive patients. However, the reduction of BP and the achievement of target BP and cardiovascular outcomes in the benidipine–ARB combination group did not differ from those of the other two treatment regimens. Although recent guidelines recommend the combination of CCBs and thiazide diuretics,9, 11, 20 this combination is not widely used in current clinical practice. In fact, only four studies on this combination have been reported,15, 24, 25, 26 and a meta-analysis of the results showed a significant risk reduction for myocardial infarction and stroke compared with other combinations, whereas the effectiveness of this therapy was similar to that of other combinations in terms of reducing the risk of all-cause and cardiovascular mortality.27 Further studies to evaluate the CCB-thiazide combination and the incidence of stroke in comparison with other drug combinations will be needed to confirm the results of the present study.

Acknowledgments

The COPE trial was supported by the Japanese Society of Hypertension. Trial registration: http://clinicaltrials.gov (identifier NCT00135551) and http://www.umin.ac.jp/ctr/index-j.htm (UMIN000001152). The COPE trial was conducted as a collaborative research effort between Yamaguchi University and the sponsor Kyowa Hakko Kirin (KHK). Publication of this sub-analysis was financially supported by KHK. KHK had no role in the design, data collection, performance, interpretation or writing of this sub-analysis.

Footnotes

Supplementary Information accompanies the paper on Hypertension Research website (http://www.nature.com/hr)

Dr SU was supported by research grants from Yamaguchi Prefecture, Japan, and KHK. Dr HR was supported by research grants from Daiichi Sankyo, Astellas Pharma, Dainippon Sumitomo Pharma, Eisai, Kowa Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Otsuka Pharmaceutical, Pfizer Japan, Sanofi, Shionogi and Takeda Pharmaceutical. Dr SU received honoraria from Boehringer Ingelheim, Mochida Pharmaceutical, Takeda Pharmaceutical, Kowa Pharmaceutical, Novartis Pharma, Bayer Yakuhin and Daiichi Sankyo. Dr HR received honoraria from KHK, Astellas Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Takeda Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Shionogi, Taisho Toyama Pharmaceutical, and Bayer Yakuhin. Dr SU serves on an ad-hoc advisory board for Nippon Boehringer Ingelheim. The remaining authors declare no conflict of interest.

Contributor Information

Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group:

T Ogihara, T Saruta, R M Matsuzaki, T Eto, T Fujita, J Higaki, S Ito, A Kamiya, K Kikuchi, H Matsuoka, H Suzuki, C Tei, R H Matsuoka, H Kumagai, Y Ohashi, H Rakugi, K Shimamoto, S Takishita, S Umemoto, R K Shimada, K Hayashi, K Kario, M Kawana, K Kitagawa, H Makino, M Matsumoto, J Yoshikawa, R K Abe, H Matsuura, Y Ohashi, K Otsuka, K Tanabe, R N Suzuki, S Nogawa, K Utsunomiya, T Yoshikawa, W Yumura, R Y Ohashi, R S Umemoto, K Kikuchi, N Hasebe, M Bunya, W Fujii, N Funayama, M Gima, K Hashizume, Y Hirayama, H Matsuhashi, H Morimoto, T Myojo, K Ohori, H Omiya, T Ota, A Sato, T Shiokoshi, H Tanaka, K Yamazaki, H Yoshie, K Shimamoto, M Abiru, M Adachi, Y Fujise, K Hanawa, K Ishii, Y Kadono, T Kaku, S Kaneta, M Kato, N Kato, H Kobayashi, T Komakine, T Matsumoto, T Mita, N Miura, H Mukai, K Nagao, H Nakagawa, M Nakagawa, N Nakajima, T Nishimiya, Y Nishino, A Nunokawa, J Ohata, H Ooiwa, R Sato, S Satoh, S Shibata, M Takada, Y Takagawa, Y Takagi, S Takeichi, S Tanaka, N Togashi, N Ura, C Wakabayashi, D Yoshida, H Yoshida, K Yoshida, A Kitabatake, H Tsutsui, M Akutsu, S Fujii, T Furumoto, S Kakinoki, H Kawasaki, T Kimura, M Makiguchi, H Matsuo, H Okamoto, Y Oyama, J Shimokawa, N Tsuzuki, S Ito, Y Imai, R Domon, H Ebina, S Egawa, T Haruyama, H Hashimoto, T Hayakawa, H Inomata, Y Katahira, T Katakura, R Kikuchi, H Kimura, S Kyogoku, Y Kyogoku, K Matsuo, H Nakazawa, H Odakura, F Okuguchi, E Ohtomo, H Ouchi, M Seino, M Tadokoro, Y Tanno, N Uchida, T Yamanaka, K Yunomura, K Okumura, T Hatayama, Y Kanehira, H Kaneko, M Kimura, N Maeda, A Mikuniya, H Narita, M Ono, T Osanai, M Sato, H Yoshino, S Momomura, M Ono, M Inoue, T Iwase, K Miyazaki, M Taki, T Aizawa, Y Hasunuma, H Makino, H Okabayashi, S Hosoda, T Sumiyoshi, M Abe, Y Kira, M Nagayama, K Sakai, O Yoshikawa, M Ide, N Kimura, S Matsuzaka, Y Miyajima, K Sawai, T Sumi, R Takada, M Toma, Y Yamada, K Yoda, T Yokokawa, S Yokoyama, K Kanmatsuse, T Kushiro, T Anazawa, T Ebuchi, H Fujita, N Katsumata, K Masubuchi, T Migita, T Osada, Y Otsuka, F Saito, S Shimoda, K Sugino, A Takahashi, S Tani, K Yumi, H Daida, T Arino, T Iesaki, Y Inomata, H Nakahara, H Shiraishi, H Sudo, T Degawa, T Araki, H Itaya, H Komatsu, H Kuwana, T Mikawa, H Nomoto, N Ogawa, H Sato, H Takase, H Toyoda, M Yamamoto, K Obayashi, I Akabane, H Hamamoto, R Kanbara, H Kato, H Kimura, N Mori, K Yamada, M Yamamuro, M Isobe, H Emoto, O Inaba, T Inazawa, H Inomata, K Isobe, Y Ito, M Komura, H Kosuge, Y Maejima, N Miwa, T Nishimori, K Otomo, K Sakurai, M Sawada, M Seya, M Shimizu, T Takagi, M Tamura, K Tanaka, D Tezuka, T Tokunaga, A Yagishita, A Yamashina, T Hara, S Hayashi, Y Hirayama, Y Hirooka, M Iitaka, T Ishiyama, F Kijima, H Kobayashi, Y Kobayashi, K Kondo, T Kuwabara, M Mugishima, Y Nakayama, Y Nishizato, Y Osamura, Y Sakomura, S Saneshige, N Shindo, N Takao, Y Takata, H Tomiyama, S Ishimaru, Y Obitsu, H Shigematsu, T Baba, H Fukushima, T Hirayama, K Magari, S Makimura, T Nagae, K Osada, T Osada, T Shimizu, H Suesada, K Tamura, T Yamazaki, A Hirai, T Fukasawa, H Ono, M Yamakado, T Shiba, S Otomi, A Uehata, K Takazawa, A Aizawa, T Iketani, M Kino, H Kobayashi, T Morishima, N Sakamoto, T Sakamoto, H Yamakawa, H Kasanuki, R Nagai, T Kadowaki, J Tanaka, T Yamazaki, M Takagi, S Ui, S Baba, K Fujita, T Hasegawa, K Tajima, M Tanaka, N Yamato, I Kuwajima, K Harada, H Miyata, S Mizuno, S Ueda, K Sugi, H Ando, K Mishima, M Moroi, S Nishizawa, S Suzuki, J Yamazaki, R Nakanishi, H Nakano, K Tokuyasu, T Aoyagi, M Fujioka, N Kobayakawa, K Nakajima, A Hirayama, K Tsukamoto, Y Araki, H Hara, K Hara, T Saruya, S Umemura, M Arima, T Endo, K Furumi, Y Hatori, Y Ikeda, Y Ikeya, T Kaneda, T Kawada, T Kawano, T Kawashima, M Kihara, M Kikuta, A Kitamura, H Kobayashi, S Kobayashi, T Kuji, S Masuda, Y Minamimoto, K Minamisawa, T Mitsuhashi, N Miyazaki, Z Nagashima, T Nakatogawa, R Nakayama, N Nyui, M Ogawa, T Onishi, K Saka, T Sano, A Sato, K Shiba, F Shionoiri, H Sugiyama, H Suzuki, I Takasaki, K Tamura, Y Tokita, M Umemura, S Yamaguchi, G Yasuda, S Nakamura, K Takayanagi, T Hayashi, M Ichihara, S Kobayashi, Y Sakai, T Uchida, I Yaguchi, I Komuro, S Aoki, Y Hashimoto, C Ibuki, Y Isobe, R Kumasaka, M Matsuda, K Mizuno, D Murakami, S Nakamura, M Nakatani, T Ohba, T Ohara, T Okumura, A Saito, T Sakurai, S Sato, W Sato, K Seimiya, Y Seino, K Shimizu, M Takano, K Tokuyama, D Uchida, K Yodogawa, S Oshima, M Kurabayashi, N Baba, Y Furushima, T Goto, T Hosoi, T Iijima, K Ito, Y Iwata, H Kubo, M Matsumoto, M Miyazaki, F Naganuma, K Nakada, M Tokushima, K Tsunoda, S Wakamatsu, Y Yagihara, Y Aizawa, M Aizawa, M Aizawa, N Hayashi, T Hori, H Kobayashi, M Kodama, K Maeda, K Miura, K Okada, Y Okura, Y Sasagawa, S Takizawa, M Tamura, T Yamamoto, T Murohara, Y Awaji, H Funahashi, D Hayashi, M Iida, D Ishihara, S Ishikawa, S Kamide, M Kanashiro, N Kurebayashi, S Kyo, H Matsui, K Matsuo, M Morishima, H Noda, T Noda, N Okumura, T Ota, S Shimizu, F Somura, Y Takada, Y Takeichi, H Takezawa, T Uchikawa, D Yoshikawa, G Kimura, Y Ando, M Hoshiai, N Okuda, S Suzuki, K Takada, N Takada, K Yamada, H Hishida, T Furuta, H Hayashi, K Ito, K Kato, M Nomura, T Ota, M Ohtsuki, T Tabata, S Taga, R Tateishi, T Ito, M Fukuda, T Iwa, Y Wakida, T Yonemoto, M Watarai, M Ito, H Kawai, Y Murata, S Nomoto, K Takemoto, N Tsuboi, Y Yoshida, N Inoue, M Ishikawa, M Matsumoto, T Muramatsu, R Yoshida, M Ono, Y Hanaki, H Sano, Y Shibata, K Sakai, M Ajioka, H Asano, R Okamoto, H Osanai, Y Uemura, K Yokoi, T Tanaka, H Kamiya, K Miki, M Niwa, H Fujiwara, S Minatoguchi, T Arai, S Kato, H Kobayashi, T Minagawa, N Mori, K Nakahara, Y Shimizu, M Tadokoro, N Takahashi, T Shigemasa, I Kobayashi, T Nakano, M Ito, A Fukui, Y Higashi, T Ito, U Kano, K Makino, K Nakai, M Nakajima, T Nakajima, K Sekoguchi, T Tanaka, T Tanigawa, N Takekoshi, H Enyama, T Hirakawa, J Ito, T Ito, H Kakuda, T Kigoshi, K Kondo, K Masuya, M Matoba, A Nakagawa, T Nakahashi, H Nakato, H Okada, M Okuro, Y Takeuchi, H Tsugawa, T Urata, M Yasuhara, M Shimizu, H Ino, T Araki, N Fujino, T Haraki, K Hayashi, S Hifumi, T Konno, M Minamoto, S Miyamoto, M Mori, C Nakanishi, Y Sakamoto, K Sakata, S Takeda, K Ueda, K Uchiyama, S Takata, S Kaneko, I Aburadani, I Inoki, K Kitano, D Kobayashi, K Kontani, M Maekawa, M Maruyama, K Matsunuma, Y Nagai, Y Nagata, M Okajima, K Otowa, Y Sekiguchi, K Shinmura, S Usui, H Yokoyama, M Yonejima, K Nakao, N Hiraiwa, T Ko, I Masuda, T Nagae, K Nishino, M Sakamoto, T Kita, Y Nakagawa, T Kimura, T Doi, H Horiuchi, M Kinoshita, M Mizuno, M Ohnishi, K Shigemoto, A Wada, T Yamada, H Yoshida, M Nakagawa, H Matsubara, K Furukawa, T Hatta, A Inoue, H Katsume, A Masui, S Matsumoto, T Seki, K Takeda, Y Taniguchi, H Tsuji, Y Saito, Y Fukuoka, M Iwano, T Katsuyama, A Nakatani, Y Sakaguchi, T Konishi, T Izumi, I Toda, A Kamimoto, Y Nagai, E Matsuwaka, R Matsuwaka, K Takei, R Ueda, N Wakaki, T Iwasaka, H Hamada, S Hamada, H Koga, H Koito, K Kono, H Kurihara, J Maeda, S Morimoto, Y Takayama, T Aoyama, M Imai, T Ii, S Kashii, M Maenaka, H Ohashi, T Suyama, M Matsuda, Y Aoyagi, K Kunisada, T Mori, T Mori, J Uemura, Y Yokoi, N Morioka, T Ozaki, K Kanamasa, K Ishikawa, S Miyazaki, S Arima, T Kai, A Kurooka, I Shimada, M Takewa, M Taniguchi, R Hattori, K Haba, R Yokota, H Matsui, E Tone, H Yamahira, T Kawarabayashi, H Inaba, Y Sakaguchi, Y Yamamoto, H Ito, M Date, M Dodo, K Fujii, M Imai, K Inoue, Y Kanoh, N Komura, S Senpuku, M Takeda, H Tateyama, K Yasui, R Yoneda, H Morita, M Kawanami, A Tahara, T Sado, T Takamura, M Taniwa, Y Kitaura, M Fukuda, H Hanada, K Nakamura, K Sawada, M Yamaguchi, K Kodama, T Higo, A Hirata, M Kanzaki, S Komatsu, K Matsuo, T Murakawa, H Nakanishi, T Nemoto, M Nishio, N Ogasawara, Y Okuyama, Y Ueda, M Imanishi, Y Kitamura, T Sakakibara, H Yoshida, H Yoshimi, T Ogihara, H Rakugi, M Akiyama, Y Ikuno, N Imai, Y Imamura, T Inoyama, K Kamide, K Katahira, S Katsuya, T Katsuya, Y Kurokawa, O Matsuki, M Matsuo, T Nakamura, E Ogura, M Ohishi, R Sasaki, K Sugimoto, J Tachi, H Tanaka, H Tanaka, T Tsunetoshi, M Yoshino, M Hori, N Awata, T Fukukawa, Y Iimori, S Iwamoto, K Sawami, M Okamura, Y Kanayama, F Nagano, H Nakayama, H Suzuki, T Amano, K Tachibana, Y Arita, M Kirino, K Sakuyama, M Shukawa, Y Nishida, T Sakamoto, S Yanagi, K Hirota, T Majima, T Ota, T Tanaka, R Nohara, T Funauchi, O Isogai, S Takashima, H Koike, M Nishimoto, Y Kawase, O Tojo, Y Chimori, H Harada, H Takeoka, S Kishi, M Yokoyama, K Hirata, J Ejiri, R Emoto, Y Furuta, K Hattori, R Kuroda, N Maehashi, H Monnaka, Y Ohashi, T Okada, H Suzuki, M Takeuchi, M Ohyanagi, M Masai, T Masuyama, M Kawabata, T Kajiya, N Daito, T Fujisawa, S Fujita, M Hasegawa, M Hirakoba, T Hirano, Y Ikeda, N Imai, K Marumoto, S Masuda, T Miki, M Mitsunaga, H Mitsuoka, Y Miyachi, N Mukohara, T Nagao, K Nakada, K Nishian, S Nishioka, T Ogura, Y Onishi, K Sakaguchi, I Sano, W Sano, M Shigenobu, A Tabuchi, J Takashima, Y Taniguchi, H Uchida, T Ueda, N Urabe, H Makino, S Harada, S Hirakawa, H Hirata, J Ishii, K Koten, Y Nagake, T Nakajima, Y Nakamura, T Terami, K Mitsudo, M Fujii, K Fujita, E Iwano, K Kadota, Y Nishihara, Y Takaya, H Yamamoto, T Yamamoto, C Shigemasa, I Hisatome, T Kato, H Miyakoda, M Sakamoto, M Shimoyama, T Shimada, K Tanabe, Y Goto, Y Hanada, K Kawakami, J Kitamura, K Kitamura, H Nakata, N Oyake, H Sugiura, H Tsukihashi, M Matsuzaki, S Umemoto, S Aoyagi, H Aoyama, T Fujino, S Fukuta, N Hiroyama, Y Ikeda, Y Inamoto, R Kametani, A Kamiya, Y Kanamaru, S Kotoku, A Matsushima, J Morita, Y Murano, M Nakatsuka, S Nishimura, Y Nisnimura, T Okamura, F Okuda, U Onaka, M Ozaki, A Shimizu, C Takata, M Tamitani, T Watada, T Watada, K Yamamoto, M Yamauchi, T Yorozu, H Yoshikane, F Yoshino, J Higaki, J Doiuchi, T Fukuoka, H Hashimoto, M Igase, H Kadota, H Kaneko, S Komatsu, Y Matsubara, K Miyoshi, K Murakami, S Murao, T Niiya, T Ochi, A Satoh, T Seki, H Takahashi, T Yamashita, T Yoshino, M Kohno, N Fujita, T Fukui, T Hamamoto, K Hasegawa, H Hitomi, K Ihara, H Kiyomoto, H Masugata, I Matsumoto, N Takahashi, K Yoshikawa, Y Doi, M Arisawa, T Egawa, M Fukuda, Y Kawada, H Kusunose, T Maeda, N Minami, M Nishinaga, T Noguchi, K Okabayashi, K Sato, T Satomi, J Takada, S Tamura, T Usui, M Yamada, M Irahara, H Azuma, M Fujimura, H Fujino, M Fujino, E Harada, S Harada, Y Hiasa, S Hosokawa, K Kawahara, K Koshiba, M Murakami, Y Nakaya, H Nii, S Nozaki, A Ota, T Ozaki, K Sone, Y Tsutsui, S Ueta, M Nobuyoshi, Y Fujishima, K Hisano, H Ikezono, R Imawatari, Y Izumi, H Kanai, T Nakamura, T Nakamura, T Noda, E Ono, S Tanaka, T Tsuiki, T Yanai, T Sasaguri, S Akimitsu, K Dohmen, K Fujisawa, K Fukuyo, S Harashima, T Hayashi, M Hirata, Y Hirata, N Ikeda, H Ikematsu, W Ikematsu, W Kajiyama, Y Kawakami, I Kawasaki, H Kondo, H Kusuhara, N Maeda, H Miyahara, A Motomura, K Nakamura, T Noguchi, T Okinaga, M Sato, I Shimada, H Shin, K Soejima, K Sugi, T Taniguchi, T Uwatoku, S Yamaga, K Yamaji, J Yanagi, H Yano, K Saku, M Enomoto, T Hiratsuka, K Imoto, R Kamei, H Kanaya, M Kohara, M Kusuda, H Nishikawa, H Sako, T Imaizumi, K Yano, K Maemura, N Ashizawa, M Hazama, Y Ishida, T Ito, M Kanda, M Kimura, T Noguchi, Y Oku, S Seto, S Suzuki, H Ogawa, K Goto, K Honjio, Y Horio, H Jinnouchi, Y Kaku, S Kawano, T Kimura, Y Kiyohara, A Maki, N Matsumoto, K Misumi, T Sakamoto, K Sasaki, S Sugiyama, E Tanaka, S Uemura, C Tei, K Arima, Y Daitoku, H Eto, T Hashino, K Ichinari, Y Ikeda, A Iriki, K Kiyonaga, K Kubota, Y Makise, S Masuzaki, M Miyata, H Mizoguchi, T Niiyama, Y Samejima, and S Yonezawa

Supplementary Material

Supplementary File 1
Click here for additional data file. (168.5KB, doc)

References

  1. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545–1553. [DOI] [PubMed] [Google Scholar]
  2. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res 2005; 28: 385–407. [DOI] [PubMed] [Google Scholar]
  3. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B, Blood Pressure Lowering Treatment Trialists C. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015; 162: 184–191. [DOI] [PubMed] [Google Scholar]
  4. Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B, Blood Pressure Lowering Treatment Trialists C. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2011; 29: 4–16. [DOI] [PubMed] [Google Scholar]
  5. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S, Blood Pressure Lowering Treatment Trialists C. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121–1123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Sundstrom J, Arima H, Woodward M, Jackson R, Karmali K, Lloyd-Jones D, Baigent C, Emberson J, Rahimi K, MacMahon S, Patel A, Perkovic V, Turnbull F, Neal B, Blood Pressure Lowering Treatment Trialists C. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet 2014; 384: 591–598. [DOI] [PubMed] [Google Scholar]
  7. Koshy S, Bakris GL. Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 2000; 14: 295–301. [DOI] [PubMed] [Google Scholar]
  8. Sever PS, Messerli FH. Hypertension management 2011: optimal combination therapy. Eur Heart J 2011; 32: 2499–2506. [DOI] [PubMed] [Google Scholar]
  9. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M, Ito S, Itoh H, Iwao H, Kai H, Kario K, Kashihara N, Kawano Y, Kim-Mitsuyama S, Kimura G, Kohara K, Komuro I, Kumagai H, Matsuura H, Miura K, Morishita R, Naruse M, Node K, Ohya Y, Rakugi H, Saito I, Saitoh S, Shimada K, Shimosawa T, Suzuki H, Tamura K, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Umemura S, Japanese Society of Hypertension Committee for Guidelines for the Management of H. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253–387.24705419 [Google Scholar]
  10. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–2219.23771844 [Google Scholar]
  11. Go AS, Bauman MA, Coleman King SM, Fonarow GC, Lawrence W, Williams KA, Sanchez E. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. J Am Coll Cardiol 2014; 63: 1230–1238. [DOI] [PubMed] [Google Scholar]
  12. Turnbull F, Blood Pressure Lowering Treatment Trialists C. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527–1535. [DOI] [PubMed] [Google Scholar]
  13. Yao K, Nagashima K, Miki H. Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci 2006; 100: 243–261. [DOI] [PubMed] [Google Scholar]
  14. Ogihara T, Matsuzaki M, Matsuoka H, Shimamoto K, Shimada K, Rakugi H, Umemoto S, Kamiya A, Suzuki N, Kumagai H, Ohashi Y, Takishita S, Abe K, Saruta T. The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res 2005; 28: 331–338. [DOI] [PubMed] [Google Scholar]
  15. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 2011; 29: 1649–1659.21610513 [Google Scholar]
  16. Ogihara T, Matsuzaki M, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Combination therapy for hypertension in the elderly: a sub-analysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial. Hypertens Res 2012; 35: 441–448. [DOI] [PubMed] [Google Scholar]
  17. Umemoto S, Ogihara T, Rakugi H, Matsumoto M, Kitagawa K, Shimada K, Higaki J, Ito S, Suzuki H, Ohashi Y, Saruta T, Matsuzaki M. Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial. Hypertens Res 2013; 36: 1088–1095. [DOI] [PubMed] [Google Scholar]
  18. Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events CTG. Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial. Hypertens Res 2016; 39: 46–53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M, Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S, Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H, Umemura S, Ishimitsu T, Rakugi H, Japanese Society of Hypertension C. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3–107.19300436 [Google Scholar]
  20. Working Group on the Summit on Combination Therapy for CVDWorking Group on the Summit on Combination Therapy for CVDYusuf S Working Group on the Summit on Combination Therapy for CVDAttaran A Working Group on the Summit on Combination Therapy for CVDBosch J Working Group on the Summit on Combination Therapy for CVDJoseph P Working Group on the Summit on Combination Therapy for CVDLonn E Working Group on the Summit on Combination Therapy for CVDMcCready T Working Group on the Summit on Combination Therapy for CVDMente A Working Group on the Summit on Combination Therapy for CVDNieuwlaat R Working Group on the Summit on Combination Therapy for CVDPais P Working Group on the Summit on Combination Therapy for CVDRodgers A Working Group on the Summit on Combination Therapy for CVDSchwalm JD Working Group on the Summit on Combination Therapy for CVDSmith R Working Group on the Summit on Combination Therapy for CVDTeo K Working Group on the Summit on Combination Therapy for CVDXavier D. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J 2014; 35: 353–364. [DOI] [PubMed] [Google Scholar]
  21. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol 2013; 10: 143–155. [DOI] [PubMed] [Google Scholar]
  22. SPRINT Research GroupSPRINT Research GroupWright JT Jr SPRINT Research GroupWilliamson JD SPRINT Research GroupWhelton PK SPRINT Research GroupSnyder JK SPRINT Research GroupSink KM SPRINT Research GroupRocco MV SPRINT Research GroupReboussin DM SPRINT Research GroupRahman M SPRINT Research GroupOparil S SPRINT Research GroupLewis CE SPRINT Research GroupKimmel PL SPRINT Research GroupJohnson KC SPRINT Research GroupGoff DC Jr SPRINT Research GroupFine LJ SPRINT Research GroupCutler JA SPRINT Research GroupCushman WC SPRINT Research GroupCheung AK SPRINT Research GroupAmbrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103–2116.26551272 [Google Scholar]
  23. Rakugi H, Ogihara T, Umemoto S, Matsuzaki M, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T, Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial G. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. Hypertens Res 2013; 36: 947–958.23864054 [Google Scholar]
  24. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, group Vt. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031. [DOI] [PubMed] [Google Scholar]
  25. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, Hansson L, Magnani B, Rahn KH, Reid JL, Rodicio J, Safar M, Eckes L, Rizzini P, European Lacidipine Study on Atherosclerosis i. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422–2427. [DOI] [PubMed] [Google Scholar]
  26. Liu LZY, Liu G, Li W, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157–2172. [DOI] [PubMed] [Google Scholar]
  27. Rimoldi SF, Messerli FH, Chavez P, Stefanini GG, Scherrer U. Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: a meta-analysis. J Clin Hypertens (Greenwich) 2015; 17: 193–199. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary File 1
Click here for additional data file. (168.5KB, doc)

Articles from Hypertension Research are provided here courtesy of Nature Publishing Group

RESOURCES